Azathioprine toxicity in neuromuscular disease
- 1 January 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 36 (1) , 35
- https://doi.org/10.1212/wnl.36.1.35
Abstract
Azathioprine toxicity was examined in 64 consecutively treated patients with various neuromuscular diseases. Reversible leukopenia was seen in 14 patients (22%). Hepatotoxicity developed in six patients (9%), and a systemic reaction characterized by fever, abdominal pain, nausea, vomiting, and anorexia occurred in eight patients (12%). Toxic effects limited the dose of azathioprine in 27 patients (42%) and led to discontinuation of therapy in 13 (20%). Macrocytosis developed in 20% of patients, but did not require an adjustment in the dose. Two patients received allopurinol and azathioprine; both developed reversible leukopenia and macrocytosis. Patients with hematologic and hepatic toxicity, but not those with systemic toxicity, successfully tolerated retreatment with azathioprine. Toxicity was delayed as long as 56 weeks after starting azathioprine in some patients.This publication has 9 references indexed in Scilit:
- INCREASED DANGER OF BONE-MARROW DAMAGE IN SIMULTANEOUS AZATHIOPRINE-ALLOPURINOL THERAPY1981
- Prednisone and azathioprine for polymyositis. Long‐term followupArthritis & Rheumatism, 1981
- Macrocytosis and Pure RBC Anemia Caused by AzathioprineArchives of Pediatrics & Adolescent Medicine, 1980
- Azathioprine-related pancreatitis in patients with Crohn's diseaseGastroenterology, 1979
- National Cooperative Crohn's Disease Study: Adverse reactions to study drugsGastroenterology, 1979
- Cytotoxic Drugs in Treatment of Nonmalignant DiseasesAnnals of Internal Medicine, 1972
- Mercaptopurine hepatotoxicity in a patient with chronic active hepatitisArchives of internal medicine (1960), 1967
- Azathioprine therapy of ?autoimmune? diseasesThe American Journal of Medicine, 1966
- Hepatotoxicity of MercaptopurineJAMA, 1964